Work

SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps8624

Authors: Saad Zafar Usmani, Antje Hoering, Rachel Sexton, Sikander Ailawadhi, Jatin J. Shah, Sandi Fredette, Brian G. Durie, Jeffrey A. Zonder, Madhav V. Dhodapkar, S. Vincent Rajkumar, Anuj Kumar Mahindra, Todd M. Zimmerman, Paul G. Richardson, Robert Z. Orlowski

Institutions: Carolinas Healthcare System, Cancer Research And Biostatistics, University of Southern California, USC Norris Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Cedars-Sinai Medical Center, International Myeloma Foundation, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Yale Cancer Center, Mayo Clinic, Massachusetts General Hospital, University of Chicago, Dana-Farber Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2601100139

Cites:

Cited by: 7

Related to: 10